3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
26
Phase 3
14
Phase NA
10
Phase 1/2
6
Phase 1
5
Phase 2/3
2
Phase 4
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Neoplasms
2
NSCLC
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma
2
Solid Tumor Regardless of Localization and Stage
1
Patient Acceptance of Health Care
1
Pancreatic Neoplasms
1
Pain
1
Oropharyngeal Neoplasms
1
Neoplasms, Second Primary
1
Multiple Myeloma
1
Lymphoma, Extranodal NK-T-Cell
1
Localized Advanced Rectal Adenocarcinoma
1
Liver Neoplasms
1
HER-2 Negative Breast Cancer
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Acute Kidney Injury
1
Interventions
Capecitabine
13
Fluorouracil
11
Oxaliplatin
10
Bevacizumab
9
Leucovorin
6
Irinotecan
6
HMPL-013
4
Folfox protocol
4
Cetuximab
4
ferric carboxymaltose
3
regorafenib
2
gadolinium ethoxybenzyl DTPA
2
gadobenic acid
2
Triamcinolone
2
Standard of Care
2
Sodium Chloride
2
Radiofrequency Ablation
2
Pirinitramide
2
Morphine
2
Esomeprazole
2
Analgesia, Epidural
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
sodium phosphate
1
raltitrexed
1
polyethylene glycol 3350
1
iron isomaltoside 1000
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
gadoteridol
1
gadoterate meglumine
1
gadodiamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Colorectal Neoplasms
×
Drug Therapy
×
Clear all
NCT00510627
2017-03-03
Prometheus
Boston Scientific Corporation
Phase 4
Withdrawn